Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Oct 29;28(6):4317-4327.
doi: 10.3390/curroncol28060367.

Report from the Western Canadian Gastrointestinal Cancer Consensus Conference Virtual Education Series-Transition from Local to System Therapy and Optimal Sequencing of Systemic Therapy for HCC

Adnan Zaidi  1 , Shahid Ahmed  1 , Shahida Ahmed  2 , Bryan Brunet  1 , Janine Davies  3 , Corinne Doll  4 , Dorie-Anna Dueck  1 , Vallerie Gordon  2 , Pamela Hebbard  2 , Christina Kim  2 , Duc Le  1 , Richard Lee-Ying  4 , Howard Lim  3 , Dave Liu  5 , John Paul McGhie  6 , Karen Mulder  7 , Jason Park  2 , Daniel Renouf  3 , Devin Schellenberg  8 , Ralph P W Wong  2 , Mike Moser  9
Affiliations

Report from the Western Canadian Gastrointestinal Cancer Consensus Conference Virtual Education Series-Transition from Local to System Therapy and Optimal Sequencing of Systemic Therapy for HCC

Adnan Zaidi et al. Curr Oncol. .

Abstract

The Western Canadian Gastrointestinal Cancer Consensus Conference (WC-5) convened virtually on 10 February 2021. The WC-5 is an interactive multidisciplinary conference attended by health care professionals from across Western Canada (British Columbia, Alberta, Saskatchewan, and Manitoba) who are involved in the care of patients with gastrointestinal cancer. Surgical, medical, and radiation oncologists; pathologists; radiologists; and allied health care professionals participated in presentation and discussion sessions for the purpose of developing the recommendations presented here. This consensus statement addresses current issues in the management of hepatocellular cancer (HCC). Recommendations have been made for the transition from local to systemic therapy and the optimal sequencing of systemic regimens in the management of HCC.

Keywords: SABR; TACE; hepatocellular cancer; immunotherapy; local therapy; systemic therapy.

PubMed Disclaimer

Conflict of interest statement

J.D. has conducting clinical trials for BMS, Merck, MedImmune and Astellas Array BioPharma, and is a consultant for AstraZeneca, Eisai, Taiho and Amgen. C.K. received an unrelated research grant from Celgene Inc. and an honorarium from Amgen. H.L. received honoraria from Merck, BMS, AstraZeneca, Eisai, Taiho, Roche, Amgen and Bayer for consultant work. D.L. is a consultant for Sirtex Medical and AstraZeneca, both a speaker and consultant for Eisai, and a speaker for Ethicon Endosurgery. R.L.-Y. has had advisory roles for Eisai, Ipsen, AstraZeneca, Roche and Celgene. K.M. has an advisory role for Pfizer Canada, Eisai Inc. and Bayer Canada and has received clinical trials funding from Deciphera Pharmaceuticals, BluePrint Medicines and AstraZeneca. D.S. has received grant funding from Varian Medical, honoraria from AstraZeneca, Merck and Pfizer, and is on the advisory board for AstraZeneca. A.Z. has received travel grants from Roche and has also performed consultant work for Eisai. The remaining authors declare no conflicts of interest.

Figures

Figure 1
Figure 1
Local–regional therapy flow chart.
Figure 2
Figure 2
Systemic therapy flow chart.
See this image and copyright information in PMC

References

    1. Rahman A., Assifi M.M., Pedroso F.E., Maley W.R., Sola J., Lavu H., Winter J.M., Yeo C.J., Koniaris L.G. Is Resection Equivalent to Transplantation for Early Cirrhotic Patients with Hepatocellular Carcinoma? A Meta-Analysis. J. Gastrointest. Surg. 2012;16:1897–1909. doi: 10.1007/s11605-012-1973-8. - DOI - PubMed
    1. Fong Y., Sun R.L., Jarnagin W., Blumgart L.H. An Analysis of 412 Cases of Hepatocellular Carcinoma at a Western Center. Ann. Surg. 1999;229:790–799. doi: 10.1097/00000658-199906000-00005. - DOI - PMC - PubMed
    1. McWilliams J.P., Yamamoto S., Raman S.S., Loh C.T., Lee E., Liu D.M., Kee S.T. Percutaneous Ablation of Hepatocellular Carcinoma: Current Status. J. Vasc. Interv. Radiol. 2010;21:S204–S213. doi: 10.1016/j.jvir.2009.11.025. - DOI - PubMed
    1. Yeung R., Beaton L., Rackley T., Weber B., Hamm J., Lee R., Camborde M., Pearson M., Duzenli C., Loewen S., et al. Stereotactic Body Radiotherapy for Small Unresectable Hepatocellular Carcinomas. Clin. Oncol. 2019;31:365–373. doi: 10.1016/j.clon.2019.01.012. - DOI - PubMed
    1. Beaton L., Dunne E., Yeung R., Rackley T., Weber B., Mar C., Yong-Hing C., Yoshida E., DeVries K., Lee R., et al. Stereotactic Body Radiotherapy for Large Unresectable Hepatocellular Carcinomas—A Single Institution Phase II Study. Clin. Oncol. 2020;32:423–432. doi: 10.1016/j.clon.2020.01.028. - DOI - PubMed

Publication types